Comparison of Platelet-Rich Plasma and Prolotherapy for Plantar Fasciitis

NCT07480967 | Not Yet Recruiting DMC

• 1 other identifier: BMU/2026/20/000004
• Study Type: interventional
• Target: 68
• Locations: 1 country
• Sites: 1

Brief Summary

This randomized controlled trial evaluates the comparative effectiveness of platelet-rich plasma (PRP) therapy and prolotherapy in patients with plantar fasciitis. Both interventions are commonly used regenerative injection therapies intended to improve pain and functional outcomes in patients who do not respond adequately to conventional conservative treatments. Participants diagnosed with plantar fasciitis will be randomly assigned to receive either PRP injection or prolotherapy. The results of this study aim to identify the more effective injection therapy for improving clinical outcomes in patients with plantar fasciitis

Conditions

Planter Fasciitis

Keywords

Planter fasciitis; Prolotherapy; Platelet Rich Plasma

Outcome Measures

Primary Outcomes (1)

• Pain intensity measured by the Visual Analog Scale (VAS)

  Pain intensity will be measured using the Visual Analog Scale (VAS). The Visual Analog Scale is a validated measure of pain intensity consisting of a 10-cm line ranging from 0 to 10, where 0 represents no pain, and 10 represents the worst imaginable pain. Higher scores indicate greater pain intensity.

  Baseline, 2 weeks, 4 weeks, 3 months, 6 months

Secondary Outcomes (3)

• Foot function assessed using the Foot Function Index (FFI)

  Baseline, 2 weeks, 4 weeks, 3 months, 6 months

• Patient satisfaction score by 5-point Likert Scale

  2 weeks, 4 weeks, 3 months, 6 months

• Plantar fascial thickness measured by ultrasound

  Baseline, 2 weeks, 4 weeks, 3 months, 6 months

Study Arms (2)

Group Platelet Rich Plasma (PRP) Therapy

ACTIVE COMPARATOR

Platelet Rich plasma (PRP) therapy in patients with plantar fasciitis

Procedure: platelet-rich plasma injection

Group Prolotherapy

ACTIVE COMPARATOR

Prolotherapy in patients with plantar fasciitis

Procedure: Prolotherapy with 25% Dextrose

Interventions

platelet-rich plasma injection PROCEDURE

autologous platelet-rich plasma prepared from the participant's blood and injected into the plantar fascia under aseptic conditions.

Group Platelet Rich Plasma (PRP) Therapy

Prolotherapy with 25% Dextrose PROCEDURE

Injection of hypertonic dextrose solution into the plantar fascia at the site of maximal tenderness to stimulate tissue healing.

Group Prolotherapy

Eligibility Criteria

• Age: 18 Years - 64 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64)

You may qualify if:

• Patient with plantar fasciitis not responding to conservative therapy.

You may not qualify if:

• Patients with uncontrolled diabetes, haematological disorders, hepatitis B or C, HIV, clinical signs of acute inflammation, or septicaemia.
• Those receiving local steroid injections within one month.
• Those receiving non-steroidal anti-inflammatory medications within 72 hours.
• Platelet levels 25% below the normal level.
• Patient who had acute ankle or foot trauma, a diagnosis of calcaneal fracture, or stress fracture.

Sponsors & Collaborators

• Bangladesh Medical University: lead

Study Sites (1)

Bangladesh Medical University

Dhaka, 1000, Bangladesh

Location

Related Publications (9)

• Dohan Ehrenfest DM,Andia I,Zumstein MA,Zhang CQ,Pinto NR,Bielecki T

  BACKGROUND

• Capotosto S,Nazemi AK,Komatsu DE,Penna J

  BACKGROUND

• Ahadi T,Cham MB,Mirmoghtadaei M,Raissi GR,Janbazi L,Zoghi G

  BACKGROUND

• Michalak N,Banks D,Kane L,Siefferman J

  BACKGROUND

• Alhakami AM,Babkair RA,Sahely A,Nuhmani S

  BACKGROUND

• Tseng WC, Chen YC, Lee TM, Chen WS. Plantar Fasciitis: An Updated Review. J Med Ultrasound. 2023 Oct 6;31(4):268-274. doi: 10.4103/jmu.jmu_2_23. eCollection 2023 Oct-Dec.

  PMID: 38264606 BACKGROUND

• Ryan MB, Wong AD, Gillies JH, Wong J, Taunton JE. Sonographically guided intratendinous injections of hyperosmolar dextrose/lidocaine: a pilot study for the treatment of chronic plantar fasciitis. Br J Sports Med. 2009 Apr;43(4):303-6. doi: 10.1136/bjsm.2008.050021. Epub 2008 Nov 19.

  PMID: 19019908 BACKGROUND

• Pretorius J, Habash M, Ghobrial B, Alnajjar R, Ellanti P. Current Status and Advancements in Platelet-Rich Plasma Therapy. Cureus. 2023 Oct 17;15(10):e47176. doi: 10.7759/cureus.47176. eCollection 2023 Oct.

  PMID: 38021947 BACKGROUND

• Lai WF, Yoon CH, Chiang MT, Hong YH, Chen HC, Song W, Chin YPH. The effectiveness of dextrose prolotherapy in plantar fasciitis: A systemic review and meta-analysis. Medicine (Baltimore). 2021 Dec 23;100(51):e28216. doi: 10.1097/MD.0000000000028216.

  PMID: 34941081 BACKGROUND

Related Links

• Related Info

MeSH Terms

Interventions

Prolotherapy; Glucose

Intervention Hierarchy (Ancestors)

Complementary Therapies; Therapeutics; Hexoses; Monosaccharides; Sugars; Carbohydrates

Study Officials

• AKM Akhtaruzzaman, MD

  Bangladesh Medical University

  STUDY DIRECTOR

Central Study Contacts

Kazi Mahzabin Arin, MD

CONTACT

+8801754057689; kazimahzabinarin@bsmmu.edu.bd

AKM Akhtaruzzaman, MD

CONTACT

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: SINGLE
• Who Masked: OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Assistant Professor

Study Record Dates

• First Submitted: March 14, 2026
• First Posted: March 18, 2026
• Study Start: April 1, 2026
• Primary Completion (Estimated): August 31, 2026
• Study Completion (Estimated): February 28, 2027
• Last Updated: March 20, 2026

Record last verified: 2026-03

Data Sharing

• IPD Sharing: Will not share

Locations

BA (1)